65 results on '"Spiess, Philippe E."'
Search Results
2. Neoadjuvant platinum-based chemotherapy for clinically node-positive penile squamous cell carcinoma: An international, multicenter, real-world study.
3. Penile squamous cell carcinoma (PSCC) with elevated tumor mutational burden (TMB): A genomic landscape study.
4. Landscape of genomic alterations (GA) in urothelial bladder carcinoma (UBC) in patients of East Asian and South Asian ancestry.
5. An assessment of the penile squamous cell carcinoma surfaceome for therapeutic target discovery.
6. Extracellular domain ERBB2 (ERBB2 ECD+) mutations in urothelial bladder cancer (UBC).
7. Neoadjuvant pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer prior to radical cystectomy.
8. CDH1-mutated clinically advanced urothelial bladder cancer (UBC): A genomic landscape and real-world clinical outcome study (RWCOS).
9. Complimentary genomic, pathologic, and artificial intelligence analysis on low-grade noninvasive bladder cancer to predict downstream recurrence.
10. Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).
11. Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UCB) genomic alteration (GA) profile.
12. Preliminary results from phase Ib/II neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).
13. Novel use of ctDNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma.
14. Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (MTAP) genomic loss.
15. Racial differences in survival outcomes for early-stage (T1 tumor) penile cancer: Analysis from the Surveillance, Epidemiology, and End Results (SEER) database.
16. Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.
17. Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with clear cell RCC (ccRCC): Impact of FLCN genomic alteration (GA) status.
18. Proteogenomic and clinical implications of unique recurrent splice variants in clear cell renal cell carcinoma.
19. Does concurrent COX inhibition and immune checkpoint blockade improve clinical outcomes in patients with metastatic renal cell carcinoma (mRCC)?
20. Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).
21. Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non-FGFR3 receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).
22. Novel use of ctDNA to identify locally advanced and metastatic upper tract urothelial carcinoma.
23. Genomic landscape of MSH6-mutated clinically advanced castrate-resistant prostate cancer (mCRPC).
24. Does concurrent COX inhibition and immune checkpoint blockade improve clinical outcome in patients with metastatic renal cell carcinoma?
25. Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study.
26. Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer.
27. HHV-8 positive clinically advanced castrate-resistant prostate cancer (mCRPC): A potentially distinct molecular subset.
28. Clinically advanced penile (pSCC) and male urethral (uSCC) squamous cell carcinoma: A comparative genomic profiling (CGP) study.
29. HPV-16 positive clinically advanced squamous cell carcinoma of the urinary bladder (mBSCC): A comprehensive genomic profiling (CGP) study.
30. Sarcomatoid (srcRCC) versus clear cell (ccRCC) renal cell carcinoma: A comparative comprehensive genomic profiling (CGP) study.
31. Genomic landscape of CDK12 mutated metastatic castrate-resistant prostate cancer (mCRPC).
32. Peri-operative morbidity and mortality in a modern series of patients treated with cytoreductive nephrectomy (CN) at five centers.
33. Impact of human papillomavirus (HPV) infection on the outcome of perioperative treatments for penile squamous-cell carcinoma (PSCC).
34. Treatment patterns and outcomes of patients with penile squamous-cell carcinoma (PSCC) undergoing inguinal lymph node dissection (ILND): An analysis of a multicenter contemporary database.
35. Preoperative metastatic disease burden to predict overall survival following cytoreductive nephrectomy independent of IMDC risk category.
36. Association of positive Ki-67 and PD-L1 expressions in post neoadjvuant chemotherapy (NAC) radical cystectomy samples with lack of tumor downstaging (TD) and shorter overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC).
37. Development of a risk calculator of recurrence in inguinal lymph node metastatic (ILNM) patients with surgically resected penile squamous cell carcinoma (PSCC).
38. Expectations for overall survival in mRCC patients who were selected for upfront cytoreductive nephrectomy in the targeted therapy era.
39. Regression tree analysis to identify the best candidates for neoadjuvant chemotherapy (NAC) in patients with clinically lymph node-positive penile squamous cell carcinoma (PSCC).
40. Real-world data validation for differential expression of immunoregulatory molecules and targetable cancer genes may provide therapeutic insights into agnostic-driven trial designs.
41. Improving the Prognostic Ability for Personalized Therapeutic Approaches in Nonseminomatous Germ Cell Tumors
42. Predicting overall survival (OS) in patients (pts) with penile squamous cell carcinoma (PSCC) undergoing regional lymph node dissection (LND) ± multimodal therapy.
43. Impact of perioperative chemotherapy and radiation for locally advanced penile squamous cell carcinoma (PSCC).
44. Treatment patterns and impact of race in patients receiving first-line therapy for advanced penile squamous cell carcinoma (PSCC).
45. Management of renal masses in an octogenarian cohort: Is there a right approach?
46. Presence and percentage of type 2 papillary RCC in mixed (type 1 and type 2) papillary renal cell carcinoma does not portend worse prognosis in patients treated by partial/radical nephrectomy in non-metastatic disease.
47. Role of cytoreductive nephrectomy in renal cell cancer (RCC) with venous tumor thrombus.
48. Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison
49. Effect of green tea catechins in prostate cancer chemoprevention.
50. Patterns of lymphatic metastases in upper tract urothelial carcinoma: Experience from three comprehensive cancer centers.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.